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DOI 10.1016/j.ccr.2011.04.017SUMMARYMultiple mechanisms have been proposed to explain how Rb and p53 tumor suppressor loss lead to chro-
mosome instability (CIN). It was recently shown that Rb pathway inhibition causes overexpression of the
mitotic checkpoint geneMad2, but whether Mad2 overexpression is required to generate CIN in this context
is unknown. Here, we show that CIN in cultured cells lacking Rb family proteins requires Mad2 upregulation
and that this upregulation is also necessary for CIN and tumor progression in vivo. Mad2 is also repressed by
p53 and its upregulation is required for CIN in a p53 mutant tumor model. These results demonstrate that
Mad2 overexpression is a critical mediator of the CIN observed upon inactivation of two major tumor
suppressor pathways.INTRODUCTION
Tumor initiation and progression are multistep processes asso-
ciated with multiple genetic and epigenetic alterations (Hanahan
and Weinberg, 2011). One common alteration tightly associated
with human cancer is abnormal chromosome numbers or aneu-
ploidy. Since the 1800s, researchers have observed that cancer
cells missegregate their chromosomes during mitosis and that
such missegregation events are more prevalent in advanced
stages of the disease. It is not until recently, however, that the
causative role of aneuploidy in tumor initiation has been estab-
lished in animal models: at least 24 independent genetic lesions
which lead to aneuploidy also initiate or enhance the progression
of tumorigenesis in mice (Schvartzman et al., 2010). Aneuploidy
likely leads to the loss of tumor suppressors or gain of oncogenic
signals and indeed in one mouse model, enhancing aneuploidy
leads to accelerated loss of heterozygosity of the p53 tumor
suppressor locus (Baker et al., 2009).
How aneuploidy arises in tumors is still a matter of debate. It
has been postulated that this occurs by mitotic checkpoint
loss or weakness. In fact, loss of a number of key mitotic check-Significance
Chromosome instability (CIN) is thought to be themajor evolutio
overexpression of the mitotic checkpoint gene Mad2 is requi
pathways, two pathways frequently inactivated in human c
hardwired into loss of themajor tumor suppressor pathways via
bition of these tumor suppressor pathways in the early stag
presence of CIN in tumors in the absence of other genetic
aneuploid cells.point genes leads to aneuploidy and tumorigenesis in mice
(Schvartzman et al., 2010). However, data from human tumors
does not support this hypothesis as loss or weakness of the
mitotic checkpoint is rare in clinical samples (Rhodes et al.,
2007).
An unsuspected connection between a tumor suppressor
pathway and the acquisition of aneuploidy is the fact that inhibi-
tion of the Rb tumor suppressor pathway and E2F activation
directly lead to enhanced expression of the mitotic checkpoint
gene Mad2 (Hernando et al., 2004). Mad2 overexpression is
sufficient to cause nondisjunction, aneuploidy and tumor initia-
tion in mice (Sotillo et al., 2007). Thus, loss of at least one of
the major tumor suppressor pathways is hardwired to a pathway
which directly leads to CIN during mitosis. Three recent reports
propose an alternative mechanism by which Rb pathway inhibi-
tion leads to CIN via centromeric chromatin decondensation but
whether this is necessary for establishing CIN remains unknown
(Coschi et al., 2010; Manning et al., 2010; van Harn et al., 2010)
(see also Discussion).
The p53 pathway is a second pathway that has long been
recognized as a primary suppressor of CIN. In vitro, p53 lossnary driving force for tumor progression. Here, we show that
red for the CIN observed upon inhibition of the Rb and p53
ancer. Our results demonstrate that acquisition of CIN is
hyperactivation of themitotic checkpoint pathway. The inhi-
es of cancer progression may account for the widespread
events and underscores the therapeutic value of targeting
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Mad2 Mediates CIN upon Tumor Suppressor Lossor mutation results in loss of cell cycle control and aneuploidy
(Negrini et al., 2010). Genetic disruption of p53 function in the
mouse has been shown to cause CIN and accelerate tumor
development in models of various types of cancer (Donehower
and Lozano, 2009). Additionally, strong correlations between
abnormal p53 status and aneuploidy have been observed in
human tumors (Junttila and Evan, 2009).
The dissection of the mechanism by which p53 prevents
genomic instability is complicated by the fact that p53 executes
other cellular functions that are intricately linked, including the
induction of cell cycle arrest, apoptosis, and senescence
(Junttila and Evan, 2009). Despite this, evidence for a crucial
role of p21Waf1/Cip1/Sdi1 (p21), whose expression is directly
induced by p53, has accumulated. For example, mice carrying
mutant p53R172P knockin alleles, which maintain the ability to
induce p21 yet are unable to trigger apoptosis, develop tumors
with stable, diploid genomes; however, tumors that develop in
mice carrying the same mutation in a p21/ background are
invariably aneuploid (Barboza et al., 2006). This suggests that
part, if not all, of p53’s function to maintain genomic stability is
executed by p21.
While the p53 and Rb pathways are often studied indepen-
dently, the relevance of crosstalk between these major tumor
suppressor pathways is increasingly recognized (Polager and
Ginsberg, 2009). p21 represents an obvious connection between
the two pathways as its expression is directly induced by p53
and, as a cyclin-dependent kinase inhibitor, p21 retains the Rb
family of pocket proteins in a hypophosphorylated state, thus
preventing unscheduled E2F activation and cell cycle entry.
The notion that p53 maintains genomic stability largely, if not
exclusively, by p21 induction suggests that p53 may prevent
CIN through a p21-cyclin/Cdk-Rb-E2F repression pathway.
Because increased Mad2 expression, a primary cause of CIN,
is a direct result of aberrant Rb pathway signaling, disruption
of p53 function may also cause CIN through elevated levels of
Mad2.
While Mad2 overexpression is sufficient to initiate tumorigen-
esis, whether it is necessary for the tumorigenic effects of Rb
or p53 pathway inhibition and the nature of these effects have
not been previously explored. The experiments presented here
address this hypothesis.
RESULTS
p53 Represses Mad2 Expression by Induction of p21
Rb inactivation results in upregulation of Mad2 (Hernando et al.,
2004), a direct E2F target, and Mad2 overexpression leads to
CIN both in vitro and in vivo (Sotillo et al., 2007). Disruption of
the p53 pathway, directly or indirectly, leads to and maintains
CIN (Donehower et al., 1995; Thompson and Compton, 2010;
Tomasini et al., 2008). To determine whether Mad2 overexpres-
sion plays a role in the acquisition of CIN observed upon p53
inactivation, we first analyzed Mad2 protein levels in primary
mouse embryonic fibroblasts (MEFs) derived from wild-type,
p53+/ and p53/ mice. p53+/ and p53/ MEFs expressed
higher levels of Mad2 than wild-type cells (Figure 1A). Consistent
with previous studies showing that p53 or p21 loss does not lead
to changes in the distribution of cells in G1, S, G2, or M phase of
the cell cycle (Deng et al., 1995), levels of phosphohistone H3702 Cancer Cell 19, 701–714, June 14, 2011 ª2011 Elsevier Inc.(Ser10), a mitotic marker, were similar for the three genotypes.
Additionally, Mad2 levels were elevated in mitotic as well as in
nonmitotic cells (see Figure S1A available online). This indicates
that the increase in Mad2 levels is not merely a result of an
increase in the fraction of mitotic cells. The levels of BubR1,
another mitotic checkpoint protein, were equally elevated,
implying that BubR1 expression is controlled by p53 in a similar
manner (see also Discussion).
In order to test whether p53 is able to directly repress Mad2
promoter activity, a p53 expression vector and a vector in which
luciferase expression is driven by 235 base pairs of the Mad2
promoter were cotransfected into HCT116 cells. Compared
with the empty vector control, p53 effectively repressed
promoter activity in a dose-dependent manner. In contrast,
mutant p53V143A, which does not bind to p53 DNA binding
elements (Zambetti and Levine, 1993), was unable to do so (Fig-
ure 1B). Similar results were obtained using Saos2 cells (data not
shown). Sequence analysis of the Mad2 promoter revealed the
presence of a putative p53 binding site approximately 160
base pairs upstream of the transcription start site. However,
mutation of this site did not affect p53-mediated repression
(data not shown). These results suggest that p53-mediated
Mad2 repression is dependent on its ability to bind to DNA but
that this effect is mediated through other transcriptional targets
of p53.
Because p21 is a primary transcriptional target of p53, we
asked whether Mad2 protein levels were also elevated in MEFs
lacking one or both copies of the CDKN1A gene, which encodes
p21. Indeed, both p21+/ and p21/ cells expressed higher
levels of Mad2 than wild-type MEFs (Figure 1C). Similar to our
observations in p53+/ and p53/ MEFs, BubR1 levels were
also elevated, whereas phosphohistone H3 levels did not
change in p21+/ or p21/ cells, again confirming that Mad2
was not elevated as a consequence of an increase in the fraction
of mitotic cells (Deng et al., 1995). In addition, as seen with wild-
type p53, p21 repressed Mad2 promoter activity in reporter
assays that contained 235 base pairs of the Mad2 promoter
(Figures 1D and 1E). Loss of either both p53 alleles or both p21
alleles by means of homologous recombination in human
HCT116 cells leads to a 2.5- to 3-fold increase inMad2 promoter
activity (Figure S1B) and a 1.5-fold increase in endogenous
Mad2 mRNA levels (Figure S1C). Since p21 induction by p53 is
dependent on its DNA binding activity, these results suggest
that p53 represses Mad2 expression through induction of p21.
Consistent with this, p53’s ability to repress Mad2 promoter
activity in HCT116-p21+/+ cells was significantly diminished in
a p21/ background (Figure 1F). The residual repressive activity
was the result of the ability of p53 to induce apoptosis as a p53
mutant that is able to induce p21 expression but unable to
induce apoptosis (p53R175P) (Liu et al., 2004) completely lost
repressive activity in the absence of p21 (Figure 1F). Thus,
we conclude that p53 represses Mad2 expression by induction
of p21.
p53 Represses Mad2 Expression through Crosstalk
to the Rb Pathway
Since p21 functions as a Cdk inhibitor, we next askedwhether its
effect on theMad2 promoter was dependent on pocket proteins
by overexpressing p21 in Rb triple knockout (TKO) MEFs, in
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Figure 1. P53 Represses Mad2 Expression by Induction of P21
(A) Western blot of primary mouse embryonic fibroblasts (MEFs) derived from wild-type, p53+/, or p53/ embryos. H2AX serves as loading control for
phosphohistone H3 (Ser10; pHH3).
(B) Reporter assays showing repressive activity of wild-type and mutant p53 on the Mad2 promoter. HCT116 cells were cotransfected with a firefly luciferase
vector in which luciferase expression is controlled by 235 bp of the humanMad2 promoter and an expression vector containing either wild-type p53 or the DNA-
binding deficient mutant p53V143A (see also E). Renilla luciferase and GFP expressing vectors were cotransfected for normalization of transfection efficiency (top)
and exogenous p53 protein expression (western blots below). Triangles indicate increasing amounts of transfected p53. Means ± SD are shown for assays
performed in triplicate.
(C) Western blot of MEFs derived from wild-type, p21+/, or p21/ embryos. H2AX serves as loading control for phosphohistone H3 (pHH3).
(D) Reporter assays as in (B) using a p21 expression vector. Means ± SD are shown.
(E) Genomic structure of the Mad2 gene and the luciferase reporter construct containing 235 base pairs of the Mad2 promoter. E2F, putative E2F binding site;
CHR, cell cycle homology region; CDE, cell cycle-dependent element (see also text for details).
(F) Reporter assays as in (B) using HCT116-p21+/+ or HCT116-p21/ cells and expression vectors containing no insert (Vect.), wild-type p53 (WT), DNA-binding
deficient p53V143A (VA) or the p53R175Pmutant (RP), which can induce p21 expression but not apoptosis (Liu et al., 2004 andwestern blots below). Means ± SD are
shown.
See also Figure S1.
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Mad2 Mediates CIN upon Tumor Suppressor Losswhich all three pocket protein genes are deleted (Dannenberg
et al., 2000; Sage et al., 2003). TKO MEFs were transduced
with a lentiviral vector containing the reverse tetracycline trans-
activator (rtTA) cDNA under control of a ubiquitous promoter
and a p21 cDNA whose expression is controlled by a tetracy-
cline-responsive promoter. Following selection for transduced
cells, doxycycline was added to the culture medium and cells
were harvested at different time points thereafter. While p21
expression increased over time, Mad2 protein levels did not
significantly change in TKO cells (Figure 2A; Figure S2A). As
expected, Mad2 levels decreased following induction of exoge-
nous p21 expression in wild-type control MEFs (Figure 2A; Fig-
ure S2A). Flow cytometry analysis of the TKO cells at each
time point did not show significant changes in the cell cycle
profiles, indicating that the TKO cells had not arrested or entered
senescence (Figure S2B). Thus, p21-mediated repression of
Mad2 is pocket protein dependent.To further assess the contribution of pocket protein-indepen-
dent effects of p21, we made use of a series of p21 mutants.
Three domains in p21 have been implicated in its binding to
cyclin/Cdk complexes, a requirement for p21-mediated inhibi-
tion of Cdk activity. Cy1 and Cy2 are cyclin binding domains
and the K domain mediates Cdk binding. Mutations in each
of these domains individually or combinations thereof lead to
varying degrees of decrease in cyclin/Cdk binding activity
toward different cyclin/Cdk complexes (cyclin A/Cdk2, cyclin
D1/Cdk4, cyclin E/Cdk2) (Chen et al., 1996). However, if such
p21 mutants are able to repress Mad2 promoter activity, this
would suggest that p21 is able to repress in a manner indepen-
dent of the Rb pathway. Reporter assays using HCT116-p21/
and HCT116-p21+/+ cells and p21 variants containing mutations
in the Cy1, K, or Cy2 domains, individually or in combination,
showed that six different mutants in which the Cdk binding
affinity was reduced 3.5 to greater than 300-fold showed noCancer Cell 19, 701–714, June 14, 2011 ª2011 Elsevier Inc. 703
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Figure 2. P53 Represses Mad2 Expression
through Crosstalk to the Rb Pathway
(A) Top:Westernblot ofRb triple knockout (p107/,
p130/, pRb/; TKO) and wild-type (WT) MEFs
overexpressing p21 (Dox (hrs) indicates time after
induction). Bottom: Quantification of western blots
shown in upper panels. Relative levels of Mad2 and
p21 proteins are each normalized to actin on the
same blot. See also Figure S2A.
(B) Reporter assays as in Figure 1B using HCT116-
p21/ cells and mutant p21 expression vectors.
Wild-type p21 (green) and p21 containing muta-
tions in the cyclin binding domains Cy1 and/or Cy2
(mCy1, mCy2) and/or the kinase binding domain K
(mK) (red) were assayed for their ability to repress
Mad2 promoter activity. Means ± SD are shown.
Numbers above each bar indicate the fold
decrease in Cdk binding activity (green, red) as
a result of the respective mutation(s), as deter-
mined by Chen et al., 1996. Western blots below
show relative expression of exogenous wild-type
and mutant p21 with respect to GFP.
(C) Electrophoretic mobility shift assay (EMSA) of
CHR-CDE/E2F elements in the Mad2 promoter.
Top: wild-type or mutant CHR (mCHR) labeled
probes encompassing the CHR-CDE/E2F ele-
ments in the Mad2 promoter were incubated with
HeLa nuclear extract (extract) and antibodies
specific for E2F-4 or E2F-5 (a-E2F4, a-E2F5), as
indicated. Bottom: fold change in ratio of the
intensities of band A/B.
See also Figure S2.
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Mad2 Mediates CIN upon Tumor Suppressor Losscapacity to repress theMad2 promoter (Figure 2B; Figure S2C).
One mutant, p21mCy2, retained its capacity to repress Mad2.
However, this mutant only showed a 29% reduction in Cdk
binding affinity (Chen et al., 1996). While it is possible that any
given mutation which disrupts the ability of p21 to bind to or
inhibit Cdks might also affect its ability to signal through an
Rb-independent pathway, this seems remote given the fact
that multiple p21 mutations show the same phenotype.
Together, the above results suggest that p21 represses Mad2
expression through canonical signaling, i.e., inhibition of the
Cdk-mediated phosphorylation of Rb and consequent stabiliza-
tion of the Rb/E2F complex. In addition to multiple E2F binding
sites, analysis of the Mad2 promoter revealed the presence of
a cell cycle gene homology region (CHR) and a cell cycle-depen-
dent element (CDE) close to the transcription start site (Figures
S2F and S2G). CHR and CDE elements are also present and
conserved in a number of cell cycle-regulated genes. A protein
complex referred to as CDF1 (cell cycle-dependent factor 1) is
recruited to CHR and CDE elements and, at least for one
promoter, p21 has been shown to be recruited to these elements
where it mediates transcriptional repression of the downstream
gene (Fung and Poon, 2005; Liu et al., 1997; Vigneron et al.,704 Cancer Cell 19, 701–714, June 14, 2011 ª2011 Elsevier Inc.2006). We refer to this as the noncanoni-
cal p21 repression pathway.
Disruption of either CHR or CDE ele-
ments led to derepression of the Mad2
promoter (Figure S2D, upper) (Liu et al.,
1997) suggesting that these elementsalso play an inhibitory role. However, this derepression was
dependent on an upstream E2F binding site, since a smaller
reporter construct that lacked this upstream element failed to
show derepression when the CHR or CDE sites were mutated
(Figure S2D, lower).
Supporting the hypothesis that p21 repressed Mad2 expres-
sion through the CHR and CDE elements, p21-mediated
repression was completely lost when either site was mutated
(Figure S2E). However, the CHR element adjacent to the CDE/
E2F site might be required to stabilize E2F/Rb inhibitory
complexes. We therefore asked whether mutation of the CHR
site affected E2F binding, whose binding site overlaps only
with the CDE site. First, using an unbiased protein affinity purifi-
cation protocol followed by mass spectrometric protein identifi-
cation, we found that none of the activating E2Fs (E2F1, 2, 3a)
and only repressor E2Fs E2F4 and E2F5 bound to repeats of
wild-type CHR-CDE DNA sequences. In addition, binding of
these E2Fs was enriched for the wild-type CHR-E2F/CDE bait
sequence as compared to the mCHR-E2F/CDE sequence in
which the CHR site wasmutated (Figure S2H). We also identified
E2F binding partner DP-1, Rb family member p107, which is
known to preferentially bind to E2F4 and E2F5 (Ikeda et al.,
WT
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Figure 3. Normalization of Mad2 levels in TKO
MEFs
(A) Western blot showing Mad2 levels in wild-type (WT),
Mad2 heterozygote (Mad2+/), and Rb, p107 and p130
triple (TKO), single and double p107 and p130 knockout
MEFs. Actin and a larger molecular weight nonspecific
band serve as a loading control.
(B) Western blot and quantification of Mad2 levels in wild-
type (WT1 and WT2) and TKO MEFs transduced with
lentiviral vectors expressing sh-scrambled control (Ctrl),
sh-Mad2#1, sh-Mad2#2 and sh-Mad2#3. Levels are
normalized to Actin.
(C) 3T3 proliferation assay for TKO MEFs transduced with
corresponding short hairpin lentiviral vectors. Averages ±
SD of two independent experiments are shown.
(D) Colony formation assay and quantification of colonies
for TKO Control, shMad2#1, shMad2#2 and shMad2#3
vectors. Averages ± SEM of two independent experiments
are shown (p < 0.002 for shMad2#3, all others p > 0.4;
unpaired t test).
See also Figure S3.
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Mad2 Mediates CIN upon Tumor Suppressor Loss1996; Moberg et al., 1996), cyclin B1, cyclin-dependent kinase-1
(Cdk1), Cdk2, and the transcriptional repressor HDAC1 (Fig-
ure S2H). These observations were confirmed for E2F4 and
p107 by ChIP analysis (Figure S2I). In contrast to the mass spec-
trometry analysis, this assay is not quantitative and also likely
includes E2F4, p107, and/or p130 precipitated from more
upstream E2F sites. Cyclin B1 binding to the CHR-CDE/E2F
site was also confirmed by electrophoretic mobility shift assay
(EMSA) using a supershifting antibody (data not shown). EMSAs
using a wild-type and a mutant CHR (mCHR) probe also showed
that a high molecular weight protein complex containing E2F4
bound to the wild-type but not to the mCHR probe (Figure 2C).
These data suggest that an intact CHR site is required for the
stable formation of repressor E2F- and p107-containing
complexes that can inhibit expression of the upstream activatory
sites. This provides further support for our observations indi-
cating that Mad2 expression is repressed through canonical
Rb pathway signaling.
Mad2 Upregulation Is Necessary for the CIN Seen upon
Rb Pathway Inhibition
The above results suggest that p53 maintains adequate repres-
sion of the Mad2 gene through the Rb pathway. All three Rb
family members (Rb, p107, p130) play a role in the inhibition of
Mad2 expression, since none of the double or single knockouts
showed as high a level as seen in TKO cells (Figure 3A). Mad2
protein levels in TKO MEFs were higher both in mitotic and in
nonmitotic cells (Figure S3A) indicating that increased Mad2
levels were not simply the result of a higher mitotic fraction. To
determine whether this observed upregulation of Mad2 wasCancer Cell 19necessary for the CIN previously seen in TKO
MEFs (Gonzalo et al., 2005), we sought to
reduce the levels of Mad2 to those approaching
wild-type. Importantly, partial downregulation of
Mad2 is itself conducive to aneuploidy (Michel
et al., 2001) and complete knockdown is cell
lethal, so our intent was to achieve levels close
to those seen in wild-type cells. Using a panelof lentiviral vectors expressing short-hairpin RNAs, two
constructs (shMad2#1 and shMad2#2) were found to normalize
Mad2 levels to the desired wild-type range, as determined by
quantitative western blot analysis (Figure 3B).
Normalization of Mad2 had no effect on the high levels of
BubR1 already present in TKOMEFs (Figure S3B), again arguing
against marked decreases in the number of mitotic cells. As
a functional readout of the effect of Mad2 normalization on
mitotic checkpoint function, we challenged the different TKO
MEF lines and WT MEFs with nocodazole, a microtubule depo-
lymerizing agent. As expected, TKO MEFs transduced with
scrambled short hairpin vectors arrested in mitosis for a pro-
longed period of time (median 500 min) and normalization of
Mad2 led to a decreased median arrest time (Figure S3C). These
cells were still SAC competent, however, as previous studies
have shown that Mad2 null MEFs fail to maintain a nocodazole
arrest for more than 60 min (Burds et al., 2005), well below the
310 or 260 min seen in the Mad2 normalized TKO MEFs.
Normalization of Mad2 in TKO MEFs had no significant effect
on proliferation compared with TKO MEFs transduced with
a scrambled control vector as assessed by a 3T3 immortalization
assay (Figure 3C). In addition, a standard proliferation assay (Fig-
ure S3D) and a low-density seeding efficiency assay (Figure 3D)
failed to show significant effects of Mad2 normalization on TKO
MEF growth rates or viability. In agreement with previous
reports, near complete knockdown of Mad2 (shMad2#3) (Fig-
ure 3B) resulted in marked decreases in both viability and seed-
ing efficiency (Figures 3C and 3D) (Michel et al., 2004).
If Mad2 upregulation was responsible for the CIN in TKO
MEFs, its normalization would be expected to result in a rescue, 701–714, June 14, 2011 ª2011 Elsevier Inc. 705
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Figure 4. Mad2 Upregulation is Required for Rb Loss-Induced CIN and Accelerates Transformation of TKO MEFs
(A) Chromosome counts for sh-scrambled control and shMad2#1 TKOMEFs. Error bars indicate SD. p value as determined by nonparametricMann-Whitney test.
(B) CIN Assay. Each column corresponds to one chromosome analyzed in one colony by FISH. Scrambled shCtrl colonies in teal, shMad2#1 in orange and
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(C) Anchorage Independent Growth Assay. Averages ± SEM of two independent experiments are shown (p < 0.0037; unpaired t test).
(D) Contact Inhibition Assay. Confluent plates were transfected with an HrasV12 vector and colonies stained after 3 weeks.
(E) Intradermal Allograft Growth. Each point is the average size of 6 tumors. Averages ± SEM of two independent experiments are shown. All p values between
scrambled sh control and shMad2 curves < 0.05 (unpaired t test).
See also Figure S4 and Table S1.
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Mad2 Mediates CIN upon Tumor Suppressor Lossof this phenotype. Karyotypes of passage 25 TKO cells with
normalized levels of Mad2 were significantly less variable than
those of control TKO cells (Figure 4A). Of 20 metaphase spreads
analyzed in each condition, the distribution of chromosome
counts in scrambled-sh control TKO cells was significantly
broader than that of Mad2-normalized TKO cells. Furthermore,
none of the scrambled-sh control TKO cells had the same chro-
mosome complement while more than half of normalized Mad2
TKO cells did (Table S1). Nevertheless, this decrease in vari-
ability could be the result of subtle differences in proliferation
rate or the outgrowth of a clone of cells with a fixed karyotype.
To control for these possibilities, we directly measured the rate
of CIN bymonitoring chromosome 12 and 17 specific interphase
FISH (fluorescent in situ hybridization) in colonies of 150-500
cells derived from a single cell. In this assay, the modal number
of FISH signals in a colony reflects the karyotype of the initiating
cell and deviation from the mode is a measure of CIN rates. The
frequency distribution analysis of FISH signals for each colony
(0 to 6 or more signals for each chromosome probe) revealed
a significant decrease in the deviation from the mode in TKO
cells with normalized Mad2 levels compared with scrambled-706 Cancer Cell 19, 701–714, June 14, 2011 ª2011 Elsevier Inc.sh TKO controls (Figure 4B); 15.2% for shMad2 TKO colonies
(SEM = 1.630) and 39.5% for the shCtrl TKO colonies (SEM =
3.079) (p value < 0.005). This difference was observed in three
independent experiments with both short hairpin vectors
(shMad2#1 and shMad2#2) that had been shown to normalize
Mad2 levels. It is unlikely that we are selecting for genomically
stable clones upon Mad2 normalization since colony-forming
efficiency was unchanged in the normalized Mad2 TKO colonies
(Figure 3D) and all scrambled-sh TKO colonies analyzed showed
high deviations from the mode. These results provide direct
evidence that Mad2 upregulation is necessary for the CIN
observed in cells lacking Rb protein family function.
Mad2-Mediated CIN Accelerates Transformation
of Fibroblasts without Affecting Proliferation Rate
We next sought to investigate whether normalization of Mad2
levels in TKO cells had any effects on cellular transformation.
Transformed murine fibroblasts readily form colonies when
seeded at low density, show anchorage independent growth in
soft agar and form tumor allografts when implanted intradermi-
cally in nude mice (Flint, 2000). In addition to showing impaired
Cancer Cell
Mad2 Mediates CIN upon Tumor Suppressor Lossseeding efficiency, normalization of Mad2 in TKO MEFs trans-
duced with a retroviral vector expressing the HrasV12 oncogene
led to significant decreases in growth in soft agar and focus
formation (Figures 4C and 4D), standard assays for anchorage
independent growth and escape from contact inhibition, respec-
tively. Moreover, HrasV12 transformed TKO MEFs implanted
intradermically into immunodeficient animals form rapidly prolif-
erating fibrosarcomas (Sage et al., 2003) and Mad2 normaliza-
tion led to a significant delay in the growth of these tumors as
compared with scrambled hairpin controls (Figure 4E). This
difference likely reflects an underestimation of the effect of CIN
on allograft tumor growth since the selective pressure to main-
tain short hairpin expression (puromycin resistance) is no longer
present in vivo. In fact, Mad2 levels in the normalized allograft
tumor samples were more similar to controls than in the preim-
planted parental lines (Figure S4A). This decrease in proliferation
in vivo was not observed in vitro after HrasV12 transduction (Fig-
ure S4B), arguing that CIN induced by Mad2 upregulation plays
a role in accelerating progression through tumor-suppressive
events that are independent of proliferation per se and are only
manifest in assays of anchorage independence, contact inhibi-
tion, or implantation into recipient animals.
Mad2-Mediated CIN Is Required for the Development
of Anaplastic Tumors in a Mouse Model of Mammary
Adenocarcinoma
In order to determine what role Mad2 upregulation (as a result of
Rb pathway inhibition) plays in a setting more comparable to
common human malignancies, we focused on the previously
described WAP-T121 mammary tumor model (Simin et al.,
2004). These animals express T121, a fragment of SV40 Large
T antigen that binds to and inhibits Rb family members, under
the control of the mammary-specific Whey-Acidic-Protein
promoter. WAP-T121 females develop mammary adenocarci-
nomas with a median latency of 12 months. Pretumorigenic
mammary glands ofWAP-T121 female mice showed high levels
of Mad2 relative to their wild-type counterparts (Figure 5A), and
we sought to determine if normalization of Mad2 levels viaMad2
heterozygosity would have an effect on the characteristics
and CIN in these tumors. Pretumorigenic mammary glands
of Mad2+/;WAP-T121 females showed Mad2 levels slightly
higher than those of wild-type animals but significantly lower
than those of Mad2+/+;WAP-T121 mice (Figure 5A). Mad2
heterozygosity inWAP-T121 females resulted in a delay in tumor
onset (Figure 5B; median latency of 362 days forMad2+/+ versus
407 days for Mad2+/; p = 0.0214) and a decrease in tumor
burden compared to wild-type controls (Figure 5C; 2.2 versus
1.3 tumors per animal; p = 0.0003), both of which were statisti-
cally significant. The most striking phenotype was observed
upon analysis of tumor histology. Mad2+/+;WAP-T121 females
developed three histological types of tumors (Figures 5D and
5E): well-differentiated, adenosquamous tumors (28% of all
tumors), less differentiated, more basophillic glandular or papil-
lary adenocarcinomas (54% of all tumors), and poorly differenti-
ated anaplastic tumors (18% of all tumors) with spindle shaped
cells reminiscent of an epithelial to mesenchymal transition
(EMT) (Figure 5E). The anaplastic tumors had a similar appear-
ance to the anaplastic mammary tumors seen in humans, which
are associated with triple-negative status (estrogen, proges-terone, and EGF receptor negative) and carry a particularly
poor clinical prognosis (Reis-Filho and Tutt, 2008).
The nature of our study precludes determination of whether
the three tumor types reflect a progression from adenosqua-
mous to adenocarcinoma to anaplastic tumors, though in
many cases two of these histological patterns were observed
in the same lesion. Remarkably, Mad2 heterozygosity resulted
in a shift to a more differentiated tumor spectrum, with 48%
adenosquamous tumors, 51% adenocarcinomas, and only
1.4% (1/65) anaplastic (Figure 5D). This represents a 12-fold
reduction in anaplastic lesions that results from the loss of one
copy of the Mad2 gene. Furthermore, regardless of genotype,
adenosquamous tumors and adenocarcinomas showed base-
line moderate levels of aneuploidy as detected by chromosome
FISH for three separate chromosomes while the anaplastic
tumors seen in the Mad2 wild-type background were more
markedly aneuploid (Figures 6A and 6B). This increase in total
aneuploidy reflected both an increase in near-tetraploid as well
as of near-diploid aneuploid cells within anaplastic tumors (Fig-
ure S5A). All Mad2+/+ tumors had average Mad2 expression
levels roughly 2-fold that of Mad2+/ tumors (Figure S5B, left),
while levels of BubR1, another component of the mitotic check-
point, remained equivalent between the two genotypes (Fig-
ure S5B, right). Thus, while there is an equivalent Mad2-induced
drive toward aneuploidy in all the tumor subtypes in theMad2+/+
background, it is likely that only the anaplastic lesions have
lost the proposed aneuploidy surveillance mechanism (Torres
et al., 2007, 2010; Williams et al., 2008) which would facilitate
their survival and propagation. Alternatively, Mad2 levels may
be higher only transiently in the anaplastic tumors during the
early stages of tumor progression which could enhance the
acquisition of CIN. This is consistent with our previous observa-
tion that transient pulses of Mad2 overexpression can confer
significant instability at later stages of the disease (Sotillo et al.,
2010).
The spindle shaped cells observed in the anaplastic tumors
suggested the presence of an epithelial to mesenchymal transi-
tion (EMT), an event associated with the ability of tumors to
locally invade and metastasize. In fact, induction of EMT in
mammary epithelial cells has been shown to drivemorphological
transformation, enhanced cell migration, and tumorigenic coop-
eration with known oncogenes (Yu et al., 2009). Anaplastic
tumors in the WAP-T121 setting stained positive for markers of
EMT; loss of the epithelial marker E-cadherin and gain of the
mesenchymal marker Vimentin, as detected by coimmunofluor-
escence (Figure 6C). Conversely, adenocarcinomas remained
E-cadherin positive and Vimentin negative regardless of geno-
type. Anaplastic tumors retained the mammary specific marker
Keratin 8 (TROMA) as seen by immunohistochemistry, excluding
the possibility that they were stromal fibroblast reactions to an
epithelial lesion (Figure 6D). We did not observe notable differ-
ences in proliferation rate nor T121 transgene activation between
tumors of different histology or genotype, as determined by
immunohistochemistry for Ki67 and cyclin D1, respectively (Fig-
ure 6D). When we examined serial lung sections of all animals in
order to determine the metastatic frequency per total lung area,
anaplastic tumors in the Mad2+/+ background were significantly
more likely to metastasize compared to adenocarcinomas and
adenosquamous tumors (p = 0.0342) (Figures 6E and 6F).Cancer Cell 19, 701–714, June 14, 2011 ª2011 Elsevier Inc. 707
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Figure 5. Mad2 Upregulation Is Required for the Development of Anaplastic Mammary Tumors inWAPT121 Transgenic Mice
(A) Western blot of adult pretumorigenic mammary glands from femaleMad2+/+ andMad2+/ transgenic (WAPT121) and nontransgenic mice. Lanes 3 and 4 are
lysates from two different animals.
(B) Tumor-free survival of Mad2+/+ and Mad2+/ in WAPT121 mice. p value determined from Gehan-Breslow-Wilcoxon Test. Vertical lines indicate censored
subjects.
(C) Tumor burden (# of tumors per animal) as determined by macroscopic analysis in Mad2+/+ and Mad2+/ in WAPT121 mice. Averages ± SEM are shown.
(D) Mammary tumor type distribution inMad2+/+ (N = 65) andMad2+/ (N = 68)WAPT121mice. p value (Fisher’s test) for Adenosquamous/Anaplastic = 0.0003;
Adenocarcinoma/Anaplastic = 0.0086.
(E) Representative H&E examples of tumor types in Mad2+/+ and Mad2+/WAPT121 mice. The two anaplastic tumors shown are examples from two different
animals.
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Mad2 Mediates CIN upon Tumor Suppressor LossInhibition of p53 function by mutation or loss often correlates
with tumor progression and could explain the appearance of
anaplastic lesions. Three of 10 WAP-T121;Mad2+/+ tumors
showed p53 hotspot mutations (one adenocarcinoma and two
anaplastic tumors) but 7 of 10 showed no evidence of p53 dele-
tion or hotspot missense mutations (Figures S5C and S5D) that
could account for the distribution of the different tumor
subtypes. Overall then, these results show that in the context
of Rb pathway inhibition in the mammary gland, Mad2-mediated
CIN accelerates the progression to anaplastic adenocarci-
nomas, a clinical entity that is associated with triple-negative
state, poor prognosis, and metastatic progression.708 Cancer Cell 19, 701–714, June 14, 2011 ª2011 Elsevier Inc.Normalization of Elevated Mad2 Levels Rescues CIN
in a p53 Mutant Mouse Model
Given that p53 represses Mad2 expression largely, if not
exclusively, through p21 and crosstalk to the Rb pathway, we
wondered whether the CIN phenotype in a p53 mutant mouse
model could be rescued or alleviated by normalization of Mad2
levels. We used a previously developed p53 knockin model in
which both p53 copies are replaced by alleles expressing the
p53R172P mutant (p53C/C) (Liu et al., 2004). This mutant is defec-
tive in inducing apoptosis, yet retains the ability to induce cell
cycle arrest through induction of p21 expression (Liu et al.,
2004). Consistent with this, we found that p53R175P, the human
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Figure 6. Anaplastic Mammary Tumors in WAPT121;Mad2+/+ Mice Are Aneuploid, Invasive and More Metastatic
(A) Percent of aneuploid cells as determined by chromosome FISH in Mad2+/+ and Mad2+/ WAPT121 animals distributed by tumor type. p values calculated
using unpaired t test.
(B) Representative examples of chFISH in adenosquamous WAPT121;Mad2+/ and anaplastic WAPT121;Mad2+/+ tumors. Scale bar indicates 10 mm.
(C) Representative example of epithelial to mesenchymal transition (EMT) as determined by loss of E-cadherin and gain of Vimentin immunofluorescence staining
in an anaplastic tumor. Normal appearance (E-cadherin positive and Vimentin negative) of an adenocarcinoma is seen in lower panels.
(D) Representative examples of H&E and cyclin D1, Keratin8, and Ki67 immunohistochemistry examples from adenosquamous WAPT121;Mad2+/ and
anaplastic WAPT121;Mad2+/+ tumors.
(E) Frequency of spontaneous metastasis by tumor subtype inWAPT121;Mad2+/+mice. p value for adenocarcinomas and anaplastic tumors = 0.0342 (unpaired
t test). Error bars indicate SEM.
(F) Representative H&E examples of metastatic lesions inWAPT121;Mad2+/+ animals harboring anaplastic tumors.
See also Figure S5.
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Figure 7. Normalization of Elevated Mad2 Levels Rescues CIN in a p53 Mutant Mouse Model
(A) Reporter assays as in Figure 1B comparing p53R175P repressive activity to wild-type p53 and p21. Means ± SD are shown. Western blots below show relative
levels of exogenous p53 and p21 and relative induction of endogenous p21 expression.
(B) Western blot analysis and quantification of wild-type, p53C/C, p53C/C p21/, and p53C/C p21/ Mad2+/ MEF lysates.
(C) Lymphoma incidence in p53C/C, p53C/C p21/, and p53C/C p21/ Mad2+/ animals. p values calculated using one-sided Fisher’s exact tests. Right,
representative H&E from splenic lymphomas from mice with indicated genotypes.
(D) Percent of aneuploid cells in tumors from p53C/C, p53C/C p21/ and p53C/C p21/Mad2+/mice as determined by chromosome FISH. p values calculated
using one-sided Fisher’s exact tests.
(E) Model of Mad2 expression regulation showing crosstalk between p53 and Rb pathways via p21 action on the Mad2 promoter. An unknown protein(s) (X)
stabilizes the interaction of the repressor E2F (red)/p107 or p130 (p107/p130) complex through the CHR element. Activator E2Fs (blue) serve as transcriptional
activators at the upstream E2F binding site.
See also Figure S6.
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Mad2 Mediates CIN upon Tumor Suppressor Lossortholog of murine p53R172P, repressed Mad2 promoter activity
in human cells (Figures 1F and 7A and data not shown). P53C/C
mice develop lymphomas and sarcomas with stable, diploid
genomes (Liu et al., 2004). Interestingly, when these mice are
crossed into a p21/ background, lymphomas and sarcomas
not only develop significantly earlier, but they are also aneuploid
(Barboza et al., 2006). We hypothesized that the latter is a conse-
quence of upregulated Mad2 levels, as we had previously
observed in p21/ MEFs (Figure 1C). Western blot analysis of
MEF lysates derived from p53C/C and p53C/C;p21/ mice
confirmed that Mad2 levels were elevated in the absence of
p21 (Figure 7B). In order to reduce these elevated levels of
Mad2, we crossed p53C/C;p21/ animals with Mad2+/ mice.
In aMad2+/background, p53C/C;p21/MEFs showed reduced
Mad2 levels, comparable to those in wild-type controls, while
phosphohistone H3 levels were similar (Figure 7B; Figure S6A).
To assess whether this normalization of Mad2 levels was suffi-
cient to rescue the CIN phenotype observed in p53C/C;p21/
tumors, we monitored tumor development in p53C/C, p53C/C;
p21/ and p53C/C;p21/;Mad2+/ mice. Animals predomi-
nantly developed histiocytic sarcomas or lymphomas in the710 Cancer Cell 19, 701–714, June 14, 2011 ª2011 Elsevier Inc.spleen, thymus, and liver with no significant differences in overall
tumor latency (Figure S6B). We note that this may be due to the
fact that in our mixed genetic background a much smaller differ-
ence between latencies in p53C/C and p53C/C p21/ animals
was observed relative to the reported study in which all animals
were in a pure C57BL/6 background (Barboza et al., 2006).
However, 14% of p53C/C mice (2 out of 14) developed
lymphomas, whereas this fraction was increased to 40% in
p53C/C;p21/ mice (8 of 20). In the p53C/C;p21/;Mad2+/
background significantly fewer animals were prone to lympho-
magenesis (8%; 1 of 13 mice; p = 0.0468, one-sided Fisher’s
exact test) (Figure 7C; Figure S6C), suggesting that elevated
Mad2 levels stimulated the development of lymphomas.
To determine whether elevated Mad2 levels were mediating
the CIN in p53C/C;p21/ tumors, we analyzed the ploidy status
of the tumors using locus-specific interphase FISH on tumor
sections. In line with previous observations (Barboza et al.,
2006), tumors from p53C/C mice typically had stable, diploid
genomes, whereas in a p21/ background tumors were highly
aneuploid (Figure 7D). Normalization of Mad2 levels in p53C/C;
p21/;Mad2+/mice led to a significant reduction in the number
Cancer Cell
Mad2 Mediates CIN upon Tumor Suppressor Lossof aneuploid tumors (p = 0.0076; one-sided Fisher’s exact test).
When we subdivided the total number of aneuploid cells into
near-diploid cells and near-tetraploid cells, we noticed that in
p53C/C;p21/ tumors the numbers of near-diploid aneuploid
cells and near-tetraploid aneuploid cells were both higher
than in tumors that had developed in p53C/C or p53C/C;
p21/;Mad2+/ animals (Figure S6D). These results indicate
that elevated Mad2 levels are largely responsible for the CIN
caused by the absence of p21 and suggest that Mad2 overex-
pression is a crucial mediator of CIN in tumors with defective
p53 pathway signaling (Barboza et al., 2006; Liu et al., 2004).
DISCUSSION
While CIN has been observed in a large percentage of human
solid tumors, how it arises is now first being explored mechanis-
tically. It has been suggested that the mitotic checkpoint, whose
function is to maintain a normal chromosome complement, is
lost or weakened by mutation of its key players. Nevertheless,
it is difficult to reconcile this with the finding that mutations or
deletions of mitotic checkpoint genes are exceedingly rare in
human tumors (Perez de Castro et al., 2007; Schvartzman
et al., 2010). In fact, cancer cell lines often have a robust check-
point (Tighe et al., 2001). We have argued that overactivation of
the mitotic checkpoint is a much more frequent cause of CIN
than loss or partial loss of function. Mitotic checkpoint genes
are frequently overexpressed in human tumors (Rhodes et al.,
2007), an event that has been shown in vitro and in murine
models to lead to CIN (Hernando et al., 2004; Sotillo et al.,
2007; Thompson and Compton, 2008).
Here, we provide direct evidence that inhibition of the p53 or
Rb pathways, events that are widespread in human malignancy,
lead to upregulation of Mad2 and that this upregulation is
required for generating CIN. This is directly demonstrated by
the fact that Mad2 normalization rescues the instability observed
in these model systems.
Three recent studies show that pRb loss leads to defects in
chromosome condensation and cohesion, abnormal centromere
structure, and accumulation of DNA damage in vitro (Coschi
et al., 2010; Manning et al., 2010; van Harn et al., 2010) and
suggest that these chromosomal abnormalities lead to the
observed CIN. These seemingly contradictory results can be
reconciled if in fact mitotic checkpoint overactivation, as seen
with Mad2 upregulation, leads to these abnormalities, a hypoth-
esis that can now be tested directly. Manning et al. (2010)
reported that overexpression of E2F1 did not result in centro-
meric defects but it remains possible that this did not lead to
sufficiently high Mad2 levels to induce the effect. Alternatively,
the chromosome dynamic changes observed in vitro may not
actually be causative of the observed instability. It is also impor-
tant to note that inactivation of pRb alone leads to only a modest
increase in Mad2 (Figure 3A) (Hernando et al., 2004) and in vivo
this might not be sufficient to drive instability. Indeed, pituitary
tumors that develop in Rb+/ mice (and have lost the wild-type
Rb allele) have largely normal karyotypes (Purdie et al., 1994).
Centromeric decondensation may well lead to mitotic abnormal-
ities independent of Mad2 upregulation and be responsible for
the residual instability that was not rescued by Mad2 normaliza-
tion in TKO cells (Figure 4B).Wehave previously reported that overexpression ofMad2 also
leads to chromosome breaks and deletions (Sotillo et al., 2007).
However, it is still unclear how these are formed. We speculate
that stabilization of Securin leads to impaired Separase-depen-
dent cleavage of Cohesin. Amphitelic attachments would then
result in stress at kinetochore-microtubule attachments and at
pericentromeric chromatid regions harboring the cohesins that
were not removed by dephosphorylation during prophase.
Excess force at these points would presumably result in DNA
breaks. Pericentromeric DNA breaks of this sort have in fact
been seen in cells with spindle defects (Guerrero et al., 2010).
Homozygous loss of all three Rb family members (p107, p130
and pRb) leads to the highest Mad2 levels (Figure 3A) and
extensive CIN but p130/ cells also show strong Mad2
activation. Whether p130/ tumors are genomically unstable
has not been studied extensively but there may be a threshold
level of Mad2 required for instability achieved only upon
complete pathway inhibition. Complete pathway inhibition can
be achieved in a variety of ways, including loss of p16 or ampli-
fication of cyclin D1, and this may account for the high
percentage of human tumors that overexpressMad2 and display
CIN (Wiedemeyer et al., 2010).
CIN has long been associated with tumor progression,
aggressiveness, and invasion but the causative nature of the
effect is first beginning to be established by a wide range of
mousemodeling experiments (Schvartzman et al., 2010). Further
support is provided by our observation here that the growth of
allograft fibrosarcomas derived from HrasV12-transformed TKO
MEFs is delayed by Mad2 normalization. In addition, that Mad2
heterozygosity in the context of Rb pathway inhibition in vivo
leads to the disappearance of anaplastic lesions and a reduction
in metastatic capacity points to a role for CIN as the driver of
later tumor events, among them invasion and metastasis. We
have recently shown that Mad2 overexpression and CIN in
a KrasG12D-driven model of lung tumorigenesis promotes tumor
recurrence after oncogene withdrawal (Sotillo et al., 2010). Inter-
estingly, recent studies in yeast also suggest that aneuploid cells
show growth advantages in nonideal growth conditions or condi-
tions of stress (Pavelka et al., 2010).
We also show here that p53 represses expression of theMad2
gene via p21 induction and canonical Rb pathway signaling. The
strongest evidence for this is provided by p21 overexpression in
TKO MEFs, demonstrating a requirement of Rb pocket proteins
for Mad2 repression. That p21 mutants that are impaired in
cyclin/Cdk binding also fail to repress Mad2 promoter activity
further supports this conclusion. As shown in Figure S2E, p21
overexpression can only repress the Mad2 promoter when the
CHR and CDE/E2F sites are intact, suggesting that cell cycle
dependent and/or independent effects must be working through
these promoter elements. Our identification of repressor E2Fs,
pocket proteins, cyclin B1 and cyclin-dependent kinase-1
(CDK-1) as proteins whose binding is dependent on the CHR
site in the Mad2 promoter indicates that an as yet unidentified
protein directly stabilizes pocket protein-repressor E2F binding
to DNA via the CHR site. It is therefore tempting to speculate
that these proteins are all part of the CDF1 complex (Figure 7E).
This multiprotein repressor complex would also act to inhibit the
transcriptional enhancer located upstream, as suggested by the
observation that loss of the CHR and E2F/CDE sites leads toCancer Cell 19, 701–714, June 14, 2011 ª2011 Elsevier Inc. 711
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Mad2 Mediates CIN upon Tumor Suppressor Lossconstitutive promoter activation only in the presence of
upstream E2F sites (Figure S2D). Two observations further
suggest that this mechanism of transcriptional regulation is not
unique to Mad2, but likely also applies to other mitotic check-
point genes. First, the promoters of at least three mitotic check-
point genes, Mad2, BubR1, and CENPE contain E2F binding
sites as well as CHR and CDE sites which are highly conserved
among various vertebrate species (Figures S2F and S2G)
(Hernando et al., 2004; Polager et al., 2002; Ren et al., 2002).
Second, loss of p53 or p21 in primary cells results in an upregu-
lation of both Mad2 and BubR1, independent of the cell cycle
(Figures 1A and 1C).
Given the widespread prevalence of CIN in human solid
tumors and its role in contributing to escape from oncogene
addiction (Sotillo et al., 2010), our findings provide a mechanistic
link between necessary tumor driving events (inhibition of the
p53 or Rb pathway), tumor progression and escape from thera-
peutic intervention. Moreover, our results underscore the direct
interconnection of tumor suppressor loss and genomic insta-
bility. Strategies for targeting aneuploid cells that are likely under
stress (Tang et al., 2011) may yield drugs which will have a signif-
icant impact on cancer progression and relapse in patients.
EXPERIMENTAL PROCEDURES
Primary Cells, Cell Lines, and Cell Culture
TKO (Rb/, p107/, p130/) MEFs were derived from TKO ES cells as
described (Sage et al., 2000) (Supplemental Experimental Procedures). All
other MEFs were derived from day 12.5 embryos. Primary cells were grown
at early passages unless indicated. Mad2 knockdown was achieved with
lentiviral vectors from Open Biosystems. Mad2 knockdown, 3T3, seeding effi-
ciency, anchorage independence and focus formation assays were carried out
as described in Supplemental Experimental Procedures. Transformation of
TKO MEFs for allograft injection was carried out with a pBabe-HrasV12 retro-
viral vector. For CIN assays, TKO MEFs were plated at low density on glass
chamber slides, grown until colonies of 100-500 cells were visible and fixed
with 3:1 methanol:acetate added dropwise. FISH analysis was performed
with two pericentromeric probes from chromosomes 12 and 17.
Reporter Assays
HCT116 or Saos-2 cells were plated in 24-well plates and transfected using
Lipofectamine 2000 (Invitrogen) and calcium-phosphate precipitation (Sam-
brook and Russel, 2001), respectively. Luciferase constructs contained 235
or 204 base pairs of the human Mad2 promoter upstream of the firefly
luciferase reporter in the pGL3-Basic vector (Promega). P53 and p21 were
expressed from the pcDNA3 vector (Invitrogen). The pRL construct (Promega),
from which Renilla luciferase was constitutively expressed, was cotransfected
to correct for transfection efficiency. Firefly and Renilla luciferase activities
were measured using the Dual Luciferase Assay Reporter System (Promega)
and a Bio-Tek Clarity microplate luminometer (Bio-Tek Instruments).
Protein Analysis
Mad2 levels were determined by western blot of RIPA lysates. Antibodies used
are described in Supplemental Experimental Procedures.
Animal Husbandry
All mice were in a 129/C57BL6 mixed genetic background and kept in path-
ogen-free housing under guidelines approved by the MSKCC Institutional
Animal Care and Use Committee and Research Animal Resource Center.
Histopathology
Tissues were formalin-fixed, paraffin-embedded and sectioned at 5mm. The
primary antibodies used for immunohistochemistry were Ki67 (Vector,
1:10000), cyclin D1 (Thermo Scientific, 1:500) and Keratin 8 (TROMA). Immu-712 Cancer Cell 19, 701–714, June 14, 2011 ª2011 Elsevier Inc.nofluorescence was carried out using anti-E-cadherin (BD Transduction
2.5 mg/ml) and anti-Vimentin (Progen 0.1 mg/ml) antibodies. Hematoxylin and
eosin staining was used for standard histology analysis and all tumors
assessed without prior knowledge of genotype.
Chromosome Fluorescent In Situ Hybridization
Probes were synthesized from three pericentromeric BAC clones of chromo-
some 12 (Chr 12-RP23-54G4, RP23-41E22 and RP23 16809 5a), chromosome
16 (Chr 16-RP23-290E4, RP23-356A24 and RP24 258J4 4a) and chromosome
17 (Chr 17-RP23-354J18-6c, RP23-73N16, and RP23-202G20) and labeled
with SpectrumGreen-dUTP, SpectrumRed-dUTP, and SpectrumOrange-
dUTP (Vysis), respectively. The BAC DNAs were labeled by nick translation
according to standard protocols. The number of hybridization signals for these
probes was assessed in a minimum of 150 interphase nuclei with well-
delineated contours.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at doi:
10.1016/j.ccr.2011.04.017.
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